ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Group International a clinicalstage biotechnology company develops therapies for cancers chronic hepatitis B virus HBV and agerelated diseases in Mainland China The companys primary product candidate is HQP1351 a BCRABL inhibitor targeting BCRABL1 mutants including those with the T315I mutation It also develops APG2575 an oral administered Bcl2 selective inhibitor for hematologic malignancies and solid tumors APG115 an oral small molecule inhibitor of the MDM2p53 proteinprotein interactions to treat solid tumors and hematological malignancies and APG1252 a small molecule drug to restore apoptosis through dual inhibition of the Bcl2 and BclxL proteins for the treatment of smallcell lung cancer nonsmall cell lung cancer neuroendocrine tumor and nonHodgkins lymphoma In addition the company is developing APG1387 a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection APG2449 an oral inhibitor of FAK ROS1 and ALK kinases APG5918 an orally available and selective embryonic ectoderm development inhibitor APG265 a MDM2 protein degrader and UBX19671325 which are Bcl2 inhibitors In addition it is also involved in medical research and development clinical development clinical trial operation venture capital investment rental services and science and technology promotion services The company has collaboration relationships with biotechnology and pharmaceutical companies and research institutions Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou China